Related Experiment Videos
Single dose absorption profiles and bioavailability of two different salbutamol tablets
Arzneimittel-Forschung
|July 1, 1986
Summary
A new 4 mg salbutamol tablet (Salbutax) demonstrated comparable bioavailability to a reference product in healthy adults. Absorption profiles and peak plasma concentrations were similar, indicating equivalent therapeutic potential.
Area of Science:
- Pharmacokinetics
- Clinical Pharmacology
Background:
- Salbutamol is a widely used bronchodilator for asthma and COPD.
- Assessing the bioavailability of new generic formulations is crucial for therapeutic equivalence.
Purpose of the Study:
- To compare the absorption profiles and relative bioavailability of a new 4 mg salbutamol tablet (Salbutax) against a reference product.
- To determine if the new formulation achieves comparable therapeutic efficacy.
Main Methods:
- A single-dose, cross-over study involving twelve healthy adults.
- Measurement of salbutamol plasma concentrations over 16 hours post-dosing.
- Analysis of key pharmacokinetic parameters including Tmax, Cmax, and AUC0-16h.
Main Results:
- No significant differences were observed in Tmax or Cmax between the new tablet (Salbutax) and the reference product.
- The area under the plasma concentration-time curve (AUC0-16h) for Salbutax was marginally higher (p=0.05).
- Relative bioavailability of Salbutax was calculated at 114.3% +/- 15.7%.
Conclusions:
- The new 4 mg salbutamol tablet (Salbutax) exhibits comparable bioavailability to the reference product.
- Both formulations are considered bioequivalent, suggesting similar therapeutic outcomes.